Risk Factors for Leukopenia with Valganciclovir Prophylaxis in CMV High Risk Cardiothoracic Transplant Recipients

被引：0
|
作者：
Brueckner, A. J. [1 ]
Doligalski, C. T. [1 ]
Logan, A. T. [1 ]
机构：
[1] Tampa Gen Hosp, Pharm, Tampa, FL 33606 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2017年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1122
引用
收藏
页码：S365 / S366
页数：2
相关论文
共 50 条
  • [21] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Brueckner, A.
    Rumore, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S480 - S480
  • [22] Burden of Primary CMV Infections Remains High Despite Six Months Valganciclovir Prophylaxis in High-Risk Kidney Transplant Recipients.
    Helantera, I.
    Ortiz, F.
    Loginov, R.
    Mannonen, L.
    Lempinen, M.
    Lautenschlager, I.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 533 - 533
  • [23] Valganciclovir for CMV prophylaxis in liver transplant recipients: An initial experience.
    Berkman, SC
    Ashcraft, E
    Baillie, GM
    Taber, D
    Lin, A
    Rogers, J
    Baliga, P
    Chavin, KD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 358 - 358
  • [24] Comparison of Outcomes in Heart Transplant Recipients Receiving CMV Prophylaxis with CMV IVIG with Valganciclovir versus Valganciclovir Alone
    Moss, I.
    Rumore, A.
    Brueckner, A.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2021, 40 (04): : S115 - S116
  • [25] CMV Viremia after Discontinuation of Valganciclovir Prophylaxis in Lung Transplant Recipients
    Gift, T.
    Palafox, J.
    Jones, K.
    Imburgia, T.
    Astor, T.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S485 - S485
  • [26] Is CMV Prophylaxis Necessary in CMV Low-Risk Liver Transplant Recipients?
    Fleming, J. N.
    Bowman, L.
    Truscott, C.
    Pilch, N.
    Taber, D.
    Pote, L.
    Powderly, A.
    Mathur, S.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 474 - 474
  • [27] Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection
    Boutolleau, David
    Deback, Claire
    Bressollette-Bodin, Celine
    Varnous, Shaida
    Dhedin, Nathalie
    Barrou, Benoit
    Vernant, Jean-Paul
    Gandjbakhch, Iradj
    Imbert-Marcille, Berthe-Marie
    Agut, Henri
    ANTIVIRAL RESEARCH, 2009, 81 (02) : 174 - 179
  • [28] Low Level CMV Detection and Effectiveness of Low Dose Valganciclovir Prophylaxis in Intermediate-Risk Liver Transplant Recipients
    Nolan, A.
    Lovett, B.
    Lindner, B.
    Timpone, J. G.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 785 - 785
  • [29] Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease
    Belga, Sara
    Hernandez, Cristina
    Kabbani, Dima
    Cervera, Carlos
    TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (02)
  • [30] Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients
    Brady, R. L.
    Green, K.
    Frei, C.
    Maxwell, P.
    TRANSPLANT INFECTIOUS DISEASE, 2009, 11 (02) : 106 - 111
12345